Correlation between adverse events after drug treatment and the MDR1 C3435T polymorphism in advanced non-small cell lung cancer patients in an Asian population: a meta-analysis.

Abstract

ObjectiveTo determine the association between the multidrug resistance 1 gene (MDR1) C3435T polymorphism and adverse drug reactions in advanced non-small cell lung cancer (NSCLC) patients in Asia.MethodsLiterature about the relationship between the MDR1 C3435T polymorphism and adverse drug reactions in advanced NSCLC patients were collected from three English language databases (PubMed, Cochrane, and Embase) as well as three Chinese databases (Wanfang, China Knowledge Network, and the Chinese Biomedical Literature Database), and summarized by a meta-analysis.ResultsNSCLC patients with the T allele or TT genotype were significantly more likely to experience diarrhea than those with other genotypes under the allele model (odds ratio [OR] = 1.64, 95% confidence interval [CI]: 1.04–2.61), homozygous model (OR = 3.87, 95% CI: 1.49–10.07), and recessive model (OR = 4.48, 95% CI: 1.88–10.68). Similarly, these patients were significantly more likely to experience skin rash under the allele model (OR = 2.41, 95% CI: 1.24–4.66), homozygous model (OR = 4.77, 95% CI: 1.13–20.15), and dominant model (OR = 1.77, 95% CI: 1.03–3.05).ConclusionsAsian NSCLC patients with the MDR1 C3435T T allele or TT genotype are significantly more likely to develop diarrhea and rash after drug treatment.